SCHEMBL6080735

SCHEMBL6080735

O=C(Nc1ccc(F)c(COc2cnccn2)c1)Nc1nnc(-c2ccccc2)s1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BLM P54132 12/20 0.55
WRN Q14191 4/20 0.51
RAB9A P51151 2/20 0.50
NPC1 O15118 1/20 0.50
MCL1 Q07820 5/20 0.48
HTT P42858 4/20 0.48
SMN1; SMN2 Q16637 3/20 0.48
KMT2A Q03164 2/20 0.48
PSMD14 O00487 1/20 0.48
CYP1A2 P05177 1/20 0.48
CYP3A4 P08684 1/20 0.48
CYP2D6 P10635 1/20 0.48
MAPT P10636 1/20 0.48
CYP2C9 P11712 1/20 0.48
CYP2C19 P33261 1/20 0.48
KDM4E B2RXH2 4/20 0.47
LMNA P02545 2/20 0.47
POLB P06746 2/20 0.47
GAA P10253 2/20 0.47
HPGD P15428 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6079234 0.89 ABL1 (0.54) RAB9ANPC1HTTKMT2AMAPT
SCHEMBL6079119 0.84 ALDH1A1 (0.52) BLMHTTSMN1; SMN2KMT2AMAPT
SCHEMBL6078723 0.84 BLM (0.43) BLMWRNRAB9ANPC1HTT
SCHEMBL6079674 0.84 RAB9A (0.49) BLMWRNRAB9ANPC1HTT
SCHEMBL6079773 0.82 MAPT (0.44) BLMWRNRAB9ANPC1HTT
SCHEMBL6079515 0.82 BLM (0.42) BLMWRNRAB9ANPC1MCL1
SCHEMBL6084065 0.80 CNR1 (0.53) BLMRAB9AMCL1HTTSMN1; SMN2
SCHEMBL6079580 0.80 KCNH2 (0.38) HTTKMT2ALMNAPOLBMEN1
SCHEMBL6079940 0.80 ROCK2 (0.46) RAB9ANPC1KMT2AMAPTLMNA
SCHEMBL6204115 0.79 PTPRE (0.41) BLMWRNRAB9ANPC1HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060063782-A1 3-Hetero arylmethoxy ! pyridines and their analogues as p38 map kinase inhibitors ASTEX THERAPEUTICS LIMITED (GB) 2006-03-23 US disclosed
EP-1545523-A1 3-&-grave;(HETERO) ARYLMETHOXY ! PYRIDINES AND THEIR ANALOGUES ASP38 MAP KINASE INHIBITORS Astex Technology Limited (GB) 2005-06-29 EP disclosed
WO-2005002673-A1 RAF KINASE INHIBITORS ASTEX THERAPEUTICS LIMITED (GB) 2005-01-13 WO disclosed
WO-2004004720-A1 3-`(HETERO) ARYLMETHOXY ! PYRIDINES AND THEIR ANALOGUES AS P38 MAP KINASE INHIBITORS ASTEX TECHNOLOGY LIMITED (GB) 2004-01-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060063782-A1 3-Hetero arylmethoxy ! pyridines and their analogues as p38 map kinase inhibitors MAPK1, MAPK3, MAPK10 BLM 4296/4885WRN 3051/4885RAB9A 2580/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.